Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0649

0.0%

1:26 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

boomertree2

Pogeu Mahone

To: pro stock who wrote (12333)	8/14/2013 8:10:52 AM
From: NTTG	2 Recommendations Read Replies (1) of 13111

Not worried Pro.... Assuming the rumored patent issue is correct then PVCT will not be able to begin PIII trials any earlier than mid 2014...2~3 years to complete enrollment and data read out (for the first real glimpse of PV-10 comparative efficacy in non-aggressive stage III melanoma), another year to get analysis and reporting together, another year for filing and review, commercial product will not be out any earlier than 2019. Time is not running anywhere for PVCT, and has stopped for PVCT investors Lots of positive developments will have transpired while PVCT investors were waiting on a new synthesis patent that delayed development by 3 years, if the rumored delay is true Oh, even longer time line for HCC development, and PH-10 is officially MIA now

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next